Citigroup Inc Alnylam Pharmaceuticals, Inc. Put Options Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	SELL	$233.81 - $287.01 $11.9 Million - $14.6 Million	-50,700 Reduced 55.53%	40,600 $11.2 Million
Q2 2024 Aug 12, 2024	BUY	$143.31 - $247.0 $12.5 Million - $21.6 Million	87,300 Added 2182.5%	91,300 $22.2 Million
Q1 2024 May 10, 2024	SELL	$146.51 - $198.2 $3.08 Million - $4.16 Million	-21,000 Reduced 84.0%	4,000 $597,000
Q4 2023 Feb 09, 2024	BUY	$151.41 - $196.57 $772,191 - $1 Million	5,100 Added 25.63%	25,000 $4.79 Million
Q3 2023 Nov 09, 2023	BUY	$170.77 - $211.65 $3.4 Million - $4.21 Million	19,900 New	19,900 $3.52 Million
Q4 2022 Feb 09, 2023	BUY	$185.53 - $241.31 $4.92 Million - $6.39 Million	26,500 Added 52.48%	77,000 $18.3 Million
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $6.3 Million - $10.6 Million	45,500 Added 910.0%	50,500 $10.1 Million
Q2 2022 Aug 10, 2022	BUY	$120.42 - $169.29 $602,100 - $846,450	5,000 New	5,000 $729,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.